Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NvfiledCriticalJanssen Pharmaceutica Nv
Priority to TW083107467ApriorityCriticalpatent/TW347392B/en
Application grantedgrantedCritical
Publication of TW347392BpublicationCriticalpatent/TW347392B/en
A compound of the following formula (I) a pharmaceutically acceptable acid addition salt thereof, a N-oxide thereof, in which =a1-a2=a3-a4= is a bivalent radical of formula: (a)~(d) in which R1 is hydrogen or C1-C6-alkyl; R2 is hydrogen or C1-C6-alkyl; R3 is hydrogen or C1-C6-alkyl; AlK1 is C1-C5-alkanediyl; AlK2 is C2-C6-alkanediyl; Q is a radical of formula (aa)~(ii) in which R4 is hydrogen or cyano; R5 is hydrogen or C1-C6-alkyl; R6 is hydrogen or C1-C6-alkyl; q is 1 or 2; R13 is hydrogen or C1-C6-alkyl; and R21 and R22 each independently are hydrogen or C1-C6-alkylthio.
Complex of Ras-Farnesyltransferase Inhibitor and Sulfobutylether-7- Beta – Cyclodextrin or 2-Hydroxypropyl- Beta – Cyclodextrina and Pharmaceutical Compositions Containing the Same